Antibiotics 2017

Sessions/ Tracks

After a successful conference of Antibiotics 2016, we are currently bringing forth “3rd World Congress and Exhibition on Antibiotics and Antibiotic Resistance” (Antibiotics 2017) slated on July 31- Aug 01, 2017 at Milan, Italy. Antibiotics 2017 aims to gather the most elegant societies and industries along with the renowned and honorable persons from top universities across the globe.

Antibiotics 2017 covers various aspects of Antibiotics, The Emergence of Antimicrobial resistance, Different Types of Antibiotics, Applications of Antibiotics, Antibiotic Resistance: Opportunities and Challenges, Antibiotics for Various Diseases and Infections, Antibiotic Prophylaxis, Antibiotics: In Pregnancy and Lactation, Antibiotics in Different Industries, Modern Antibiotics: Emerging trends, Barriers and Opportunities, Drug Discovery and Novel Delivery Technologies, Antibiotics for Emerging and Re-emerging Diseases, Micro Organisms in Recent Drug Discovery, Clinical Trials of Antibiotics, Antibiotics and Mechanism, Antibiotic Regulatory Affairs and Antibiotics Market Analysis and Business Opportunities.

Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.

Antibiotic resistance invoke especially to the resistance to antibiotics that occurs in common bacteria that cause infection. The easy approach and capability of Antibiotics led to overuse in live-stock raising promotes bacteria to flourish resistance. This led to comprehensive problems with antibiotic resistance. World Health Organization (WHO) classified antimicrobial resistance as a serious hazard and no longer a indicator for the future. Antibiotic resistance is now among every part of the world and its stirring everyone irrespective to the age. When infections become resistant to first-line drugs, more costly therapies must be used. A longer duration of illness and treatment, often in hospitals, increases health care costs as well as the financial burden on families and societies. To help prevent the development of current and future bacterial resistance, it is essential to prescribe antibiotics according to the principles of antimicrobial stewardship, such as specify antibiotics only when they are needed.

Certain bacterial infections now oppose all antibiotics. The resistance problem may be reversible, but only if society begins to acknowledge how the drugs affect "good" bacteria as well as "bad". Historically, most antibacterials were used in hospitals, where they were integrated into surgical clothes and soaps to limit the spread of infection. More recently, however, those substances (including triclosan, triclocarbon and such quaternary ammonium compounds as benzalkonium chloride) have been mixed into lotions, dish-washing detergents and soaps meant for general consumers. They have also been impregnated into such items as cutting boards, toys, high chairs and mattress pads.

Antibiotics are also noted as antibacterials, are types of medications that destroy or slow down the growth of bacteria. Alexander Fleming discovered first penicillin, the first chemical compound with antibiotic properties. Some of the common antibiotics are Aminoglycosides, Cephalosporins, Carbapenems, Macrolides, Penicillin, Quinolones, Sulfonamides and, Tetracyclines etc. General fundamentals of antibiotic prescribing are use: First-line antibiotics first, Reserve broad spectrum antibiotics for marked circumstances only, prescribe antibiotics for bacterial infections if Symptoms are significant or severe.

Choice of relevant antibiotics is presently based on individual patient need. Preservation of bacterial sensitivity needs perceptive of how antibiotics select resistance. ‘Ten commandments’ which might be considered carefully when a preference has to be made for antibiotic prescribing. The compelling importance of the fact that all healthcare personnel should take ownership of the need to specify accordingly and to practice effective infection control. A realization that antibiotics may not be competent for the tasks required of them and eventually, with widespread resistance, may be incapable of the task they do today.

Antibiotics are amidst the most regularly recommended medications in modern medicine. Antibiotics are useless against viral infections. When you take antibiotics, follow the guidelines carefully. It is important to finish your medicine even if you feel improved. If you stop treatment too soon, some bacteria may survive and re-infect you. Do not save antibiotics for later or use someone else's prescription.

Antimicrobial prophylaxis is generally used by clinicians for the prevention of numerous infectious diseases. Optimal antimicrobial agents for prophylaxis should be nontoxic, inexpensive, bactericidal and active against the typical pathogens that can motive surgical site infection postoperatively. To maximize its effectiveness, intravenous perioperative prophylaxis should be carried out within 30 to 60 minutes before the surgical incision. Antimicrobial prophylaxis should be of short time to downturn toxicity and antimicrobial resistance and to reduce cost.

Antibiotics are frequently recommended during pregnancy. The specific medication must be chosen carefully, however. Some antibiotics are prescribed to take during pregnancy, while others are not. Safety depends on various factors, including the type of antibiotic, when in pregnancy you take the antibiotic, how much you take and for how long. Antibiotics normally advised safe during pregnancy: Ampicillin, Amoxicillin, Clindamycin, Erythromycin, Penicillin, Nitrofurantoin. Despite there's no direct clue that these antibiotics cause birth defects, additional research is needed. In the interim, use of these medications is still assured in some cases.

Antibiotics must be used accordingly in humans and animals because both uses share to the emergence, persistence, and escalation of resistant bacteria. Resistant bacteria in food-producing animals are of particular concern. Food animals play as a source of resistant pathogens and resistance mechanisms that can directly or indirectly result in antibiotic resistant infections in humans. Resistant bacteria may be transmitted to humans through the foods we eat. Some bacteria have turned resistant to more than one sort of antibiotic, which makes it more difficult to treat the infections they cause. Sustaining the efficiency of antibiotic drugs is vital to insulating human and animal health.

In the prior most drugs have been invented either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new access has been to recognize how disease and infection are controlled at the molecular and physiological level and to mark specific entities based on this knowledge. The process of drug discovery involves the identification of candidates, characterization, screening, synthesis, and assays for therapeutic efficacy. Evolution of an existing drug molecule from a ordinary form to a novel delivery system can significantly improve its performance in terms of patient compliance, efficacy and safety. These days, drug delivery companies are engaged in the development of numerous platform technologies to get ambitious advantage, extend patent life, and increase market share of their products. Formerly a compound has displayed its value in these tests; it will begin the process of drug development prior to clinical trials.

New diseases are originating globally and old diseases are re-emerging as Infectious agents evolve or spread, and as changes occur in conservation, socio-economic conditions, and population patterns. Likewise, many diseases thought to be decently controlled appear to be making a revival. In developed countries, public health measures such as sewage treatment, vaccination programs, sanitation and access to good medical care-including a wide range of antibiotics-have virtually disposed “traditional” diseases such as tuberculosis, diphtheria and whooping cough.

Environmental microbes are a leading source of drug discovery, and several microbial products ( anti-tumour products, antibiotics, immunosuppressants and others) are used frequently for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that the large number of microbes were not targeted for drug discovery. With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary way of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenario to swamped such constraints that might further expand the promise of drugs from environmental microbes.

Prescribing doctors are, progressively, using clinical trial data as a major source of information for evidence-based medicine for the remedy of infectious diseases, as in other clinical disciplines. However, it may be difficult to excerpt from these data the material that is needed for the management of the individual patient. At the same time, clinical trial testimony have been used, probably satisfactorily, in the process of drug registration, and the pharmaceutical industry has spent progressively large amount of money to satisfy the needs of this process. In the face of all these problems, switch in the way antibiotic clinical trials are designed and performed are clearly necessary, although this must not disturb the balance so far as to restore them less useful for those who currently derive greatest benefit from them.

Antibacterial action customarily falls within one of four mechanisms, three of which involve the inhibition or regulation of enzymes tangled in cell wall biosynthesis, nucleic acid metabolism and repair, or protein synthesis, respectively. The fourth mechanism associates the interruption of membrane structure. Many of these cellular functions targeted by antibiotics are most effective in multiplying cells. Since there is often overlap in these functions between eukaryotic mammalian cells and prokaryotic bacterial cells, it is not surprising that some antibiotics have also been found to be useful as anticancer agents.

Regulatory affairs (RA), are also called as government affairs, is a profession within regulated industries, such as medical devices, pharmaceuticals etc. Regulatory affairs also have a very specific meaning within the healthcare industries (medical devices, functional foods, biologics and pharmaceuticals). Regulatory affairs (medical affairs) professionals (aka regulatory professionals) generally have the duty for the following general areas: Ensuring that the companies obey with all of the regulations and laws pertaining to their business.

The global antibiotics market was valued at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2018, at a CAGR of 0.8%. From, 2005 this market is seen to grow at an annual rate of 6.6% until 2011. There are many companies producing antibiotics these days and there are many other antibiotics present in the market such as aminoglycoside antibiotics and it cap around 79% of the global demand. Moreover, the other antibiotics such as penicillin have 8%, streptomycin 1%, chloramnphenicol 1 %, tetracyclines 4%, erythromycin has 7%, market.

About Conference

Conference Series LLC invites all the participants from all over the world to attend ‘3rd World Congress and Exhibition on Antibiotics and Antibiotic Resistance' to be held on July 31-Aug 01, 2017 at Milan, Italy which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Conference Series LLC organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Why to attend ?

Antibiotics 2017 is a platform to discuss and learn about the latest advancements in the field of Antibiotics and Antibiotic Resistance as the world’s consideration turned regarding the urgency of new antibiotics as the antimicrobial resistance is growing day by day. Many developed nations and International health organizations are trying to focus of the current situation and making new policies to prevent the adverse effects of Antibiotic resistance.

This 2-day conference gathers researchers, academia, labs, Drug Manufacturers, government agencies, health professionals, hospitals, young investigators, pharma and labs and presents their opinions through key notes, and case study presentations. This conference lays a platform for all the researchers working in the field of Antibiotics to know the latest developments and the current situation of the Antibiotic resistance problem.

You will meet!

Food Safety Experts

Alliances of antibiotics

Public Health Preparedness Sectors

Commercialization

Strategic Drug Development

Scientific Business Communications

Medical Affairs and Networking

Executive Council of Global

Directors of Pharma Industries

Antibiotics Associations & Societies

Business Entrepreneurs

Antibiotics Researchers

Market Analysis

Summary

Antibiotics 2017 welcomes attendees, presenters, and exhibitors from all over the world to Manchester, UK. We are delighted to invite you all to attend and register for the “3rd World Congress & Exhibition on Antibiotics and Antibiotic Resistance” (Antibiotics 2017) which is going to be held during July 31- Aug 01, 2017 at Milan, Italy. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the Antibiotics 2017, where you will be sure to have a meaningful experience with scholars from around the world. All the members of Antibiotics 2017 organizing committee look forward to meet you at Milan, Italy.

Importance and Scope:

Antibiotics play a crucial role in the health of both human beings and animals. The purpose of the Antibiotic research is to stimulate discussion of new ideas and/or find new perspectives on the future of Antibiotics as there are no major Antibiotics had been discovered during the past few years. Moreover Antimicrobial resistance threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. It is an increasingly serious threat to global public health that requires action across all government sectors and society. Antimicrobial resistance is present in all parts of the world. New resistance mechanisms emerge and spread globally. Infections caused by resistant microorganisms often fail to respond to the standard treatment, resulting in prolonged illness, higher health care expenditures, and a greater risk of death.

SCOPE OF REPORT This research report categorizes the systemic antibiotics market into the following segments:

Antibiotics market (human application) by product:

Beta-lactams: ❍ Penicillin. ❍ Cephalosporins. ❍ Carbapenems.

Fluoroquinolones: ❍ Second generation. ❍ Third generation. ❍ Others.

Macrolides.

Tetracycline.

Other antibiotic classes

Antibiotics market by application:

Human applications.

Veterinary applications

Therefore it is necessary to focus on new Antibiotics and the solutions to reduce Antibiotic resistance.

Conference Highlights:

Antibiotics

The Emergence of Antimicrobial resistance

Antibiotic Resistance: Opportunities and Challenges

Different Types of Antibiotics

Applications of Antibiotics

Antibiotics for Various Diseases and Infections

Antibiotic Prophylaxis

Antibiotics: In Pregnancy and Lactation

Antibiotics in Different Industries

Modern Antibiotics

Drug Discovery and Novel Delivery Technologies

Antibiotics for Emerging and Re-emerging Diseases

Micro Organisms in Recent Drug Discovery

Clinical Trials of Antibiotics

Antibiotics and Mechanism

Antibiotic Regulatory Affairs

Antibiotics: Market Analysis & Business Opportunities

Organizations working on Antibiotics around the Globe:

Infectious Diseases Society of America

World Health Organization

U.S. Food and Drug Administration (FDA)

Center for a Livable Future (CLF)

Centers for Disease Control and Prevention (CDC)

American Medical Association

American Academy of Pediatrics

Animal Welfare Approved (AWA)

Center for Food Safety

Center for Science in the Public Interest (CSPI)

Compassion in World Farming (CIWF)

Consumers Union

Fix Food

Food Animal Concern Trust (FACT)

Soil Association

Sustain

The Humane Society of the United States (HSUS)

The Pew Charitable Trusts

Food and Water Watch

Healthy Food Action

Institute for Agriculture and Trade Policy (IATP)

Keep Antibiotics Working (KAW)

Natural Resources Defense Council (NRDC)

American Nurses Association

American Public Health Association

Institute of Medicine, National Academies of Science

American Society for Microbiology

Societies working on Antibiotics in Italy:

Italian Association for Clinical Microbiology

Italian Society of Surgery

Italian Society of Biochemistry

Istituto Guido Donegani

Istituto Sieroterapico Milanese S Belfanti

The Italian Society Of Preventive And Social Pediatrics

Italian Respiratory Society

Italian Chemical Society

Top Universities in Italy:

Scuola Normale Superiore di Pisa

Scuola Superiore Sant'Anna

Politecnico Di Milano

University of Bologna

University of Trento

Free University of Bozen - Bolzano

Sapienza University of Rome

The University of Milan

University of Padova

University of Pavia

Polytechnic University of Turin

University of Calabria

University of Milano - Bicocca

University of Salerno

University of Torino

University of Trieste

Università Politecnica delle Marche

Top Hospitals in Italy:

Istituto Oncologico Veneto

Puglia Sanità

Azienda Ospedaliera San Giovanni Addolorata

Azienda Usl di Bologna

Azienda Unità Sanitaria Locale di Reggio Emilia

L’Istituto Nazionale Neurologico “Carlo Besta

Azienda Unità Sanitaria Locale di Modena

Arcispedale S Maria Nuova Azienda Ospedaliera di Reggio Emilia V

Azienda Ospedaliera San Camillo Forlanini

Azienda Ospedaliera Mellino Mellini

Major Hospitals in Milan:

Casa di Cura San Pio X

Centro Trasfusionale dell’Ospedale Policlinico

Ospedale Fatebenefratelli

Ospedale Niguarda

Ospedale Pediatrico Vittore Buzzi

Istituto Ortopedico Gaetano Pini

Ospedale San Giuseppe

Istituto Europeo di Oncologia

Istituto Auxologico Italiano

Ospedale San Raffaele

Clinica Mangiagalli

Antibiotics: Global Markets Analysis

The global systemic antibiotics market was valued at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2018, at a CAGR of 0.8%. The global market for antifungal therapeutics was valued at $10.7 billion in 2013 and is projected to reach $12.2 billion in 2018, a five-year compound annual growth rate (CAGR) of 2.7%.

Overall sales in the current antibiotics and new products market were nearly $40 billion in 2008. It increased to $41.5 billion in 2009. By 2015, it is projected to increase to $65.5 billion, for a 5-year compound annual growth rate (CAGR) of 9.6%. The largest segment antibiotic drugs market was nearly $36 billion in 2008; this further increased to $37 billion in 2009, this projected to reach $50 billion in 2015, for a 5-year CAGR of 5.9%. Sales in the bacterial vaccines market amounted to $3.6 billion in 2008 which increased slightly to $3.9 billion in 2009. This is projected to increase to $15 billion in 2015, for a 5-year CAGR of 31.6%.

Funding for research:

From a total research fund of £13,846.1 million allotted to the UK agencies, £269.2 million (1.9%) was awarded to bacteriology projects and £95.0 million (0.7%) to antibiotics research. An additional £181.4 million was awarded to antibiotic research by the European Union, of which £85.2 million came from 2 Innovative Medicines Initiative awards.

Past Conference Report

Antibiotics 2016

Conference Series LLC hosted the “2nd World Congress and Exhibition on Antibiotics and Antibiotic Resistance” (Antibiotics 2016) during October 13-15, 2016 at Radisson BLU Hotel, Manchester Airport, Manchester, UK.

Antibiotics 2016 is specifically premeditated with a unifying axiom providing platform to widen the imminent scientific discoveries in the field of Antibiotics and Antibiotic Resistance and to deliver novel ideas besides incorporating better understanding of their role in Pharma, Drug Manufacturers, Business Management and Marketing. The scientific meeting has laid the path for the development and the validation of Antibiotics and Antibiotic Resistance under the theme of “Underlining the Hurdles Involved in Developing New Antibiotics”.

Antibiotics 2016 was privileged to acquire support from exhibitors - Radiometer Limited and BioSystems Technology.

Conference Series LLC is prerogative to thank the Organizing Committee, Editorial Board Members and Moderator – Dr. Oleg Reva, University of Pretoria, South Africa, speaker participants, poster presenters and attendees for enormous support and participation in this grand venture.

The highlights of the meeting were the eponymous lectures, delivered by the following speakers:

Byungse Suh, Temple University School of Medicine, USA

Mario A Bianchet, Johns Hopkins School of Medicine, USA

Herbert B Allen, Drexel University, USA

Andrew Cross, ACT Surfaces Ltd, UK

Samir Kumar-Singh, University of Antwerp, Belgium

By the endless support of the Journal of Drug Metabolism & Toxicology, Advances in Pharmacoepidemiology & Drug Safety, Drug Designing: Open Access and Advances in Antibiotics & Antibodies. Conference Series LLC is pleased to announce our 3rd World Congress on Antibiotics & Antibiotic Resistance, during July 31-August 02, 2017 at Milan, Italy.

Past Conference Report

Antibiotics-2015

A huge success has been achieved byOMICS Internationalin hosting “World Congress & Exhibition on Antibiotics” scheduled during September 14-16, 2015 at Las Vegas, USA with the theme “The Urgency of New Antibiotics and Control of Antibiotic Resistance”.

The annual conference brought together many eminent scientists from across 20 countries in which many critical issues were discussed in depth to provide up-to-date information to the World. On the other hand, the meeting provided a rostrum for domestic researchers to communicate with international experts which resulted in great exchange of knowledge. We would like to thank all of our wonderful speakers, conference attendees, students, associations and guests for making Antibiotics 2015 a grandiose event.

The meeting was carried out through various sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

The Vast Area of Antibiotics & Antibiotic Prophylaxis

Antibiotic Resistance: Opportunities and Challenges

Microorganisms in Recent Drug Discovery

Responsible use of Antibiotics

Optimization of Therapy-General principles

Antibiotics in Prevention and Treatment of Inflammatory and Infectious Diseases

Antibiotics: Water Born Diseases

Antibiotics and Allergies: Clinical Update

Antibiotics: Agriculture, Veterinary and Aquaculture

Antibiotics in Child care, Dental and Oral care

Antibiotics for Emerging and Re-emerging Diseases

Modern Antibiotics: Emerging Trends, Barriers and Opportunities

Antibiotics: Market Analysis & Business Opportunities

Antibiotic Regulatory Affairs

Antibiotics and Mechanism

Drug Discovery and Novel Delivery Technologies

The conference was embarked with an opening ceremony followed by workshop and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The list includes:

Exclusive session includes presentation by John M Clerici, Tiber Creek Partners, USA on “Development and procurement of biotechnology for emerging disease and engineered threats in the public health preparedness sector”

OMICS Internationalthanks all the expert presenters across the globe which includes various experts, University representatives and other eminent researchers who supported the conference by facilitating the discussion forums.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Antibiotics-2015,OMICS International is delighted to announce the next event. Mark your calendars for the upcoming extravaganza, “2nd World Congress and Exhibition on Antibiotics and Antibiotic Resistance’’ which is scheduled to organize on October 13-15, 2016 at Manchester, UK.

Be a member and support us

Highlights from last year’s Convention!

Authorization Policy

By registering for the conference you grant permission to Conferenceseries Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.